Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.


Long-Acting Cabotegravir for HIV Prevention

This podcast episode features an international expert panel discussion on key considerations for using long-acting cabotegravir as HIV PrEP.
Released: September 9, 2022

In this episode, an international expert panel shares their thoughts on key considerations for incorporating long-acting cabotegravir as an additional HIV pre-exposure prophylaxis option for appropriate individuals at high risk of acquiring HIV infection.

Topics include anticipated patient interest in this new paradigm, the role of the oral lead-in phase, new guideline recommendations for monitoring during PrEP, patient care and follow-up after PrEP discontinuation, and remaining unanswered questions.

Other episodes in this 4-part series cover additional aspects of long-acting antiretrovirals for HIV treatment and prevention, including key steps for switching patients to long-acting injectable cabotegravir plus rilpivirine for HIV treatment, such as selecting the most appropriate patients, introducing patients to the long-acting option, and preparing patients for what to expect from long-acting treatment in terms of efficacy, visit timing, and the injection experience; key considerations at the operational level for incorporating long-acting injectable ART into the HIV treatment armamentarium; and what is still needed in long-acting HIV care to further address patient needs and inequities across subgroups.

Information on this Educational Activity

Program Medium

This program has been made available online.


Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by an educational grant from
ViiV Healthcare

Related Content

Listen to Drs Jill Blumenthal and Jennifer Cocohoba discuss ART tolerability in transgender persons and the many factors to consider, from Clinical Care Options (CCO)

Jill Blumenthal, MD, MAS Jennifer Cocohoba Headshot Jennifer Cocohoba, PharmD Released: December 7, 2022

Discussion of barriers and calls to action for providing patient-centered HIV care in Malaysia from a healthcare professional and a patient advocate, from Clinical Care Options (CCO)

person default Iskandar Azwa, MBChB Andrew Tan Released: December 7, 2022

Dr Sylvia Ojoo discusses data on cryptococcal meningitis in people with HIV from the fall 2022 HIV conferences, from Clinical Care Options (CCO)

person default Sylvia Ojoo, CCST (UK), MRCP (UK), DTM&H (UK), DFFP (UK), MBChB Released: December 6, 2022

Clinical Care Options (CCO) expert audio: Drs Chloe Orkin and Babafemi Taiwo discuss new HIV data presented at IDWeek and HIV Glasgow 2022

Chloe Orkin Photo Chloe Orkin, MBChB, FRCP, MD Babafemi Taiwo, MBBS Released: December 5, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.


Cookie Settings